BOB体育

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue鈥�

Investigators

Christopher Harden, Divya C Patel

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older. If they already take nintedanib or pirfenidone for their IPF, they can continue treatment鈥�

Investigators

Christopher Harden, Divya C Patel

Status

Accepting Candidates

Ages

40 Years - N/A

Sexes

All

This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod in participants with鈥�

Investigators

Christopher Harden, Divya C Patel

Status

Accepting Candidates

Ages

18 Years - 75 Years

Sexes

All